Vertex Pharmaceuticals Incorporated has announced the appointment of Tom Graney to the role of Senior Vice President and Chief Financial Officer (CFO).
Mr. Graney will begin his role with Vertex on September 13, 2017 and will report to Executive Vice President and Chief Operating Officer Ian Smith. Mr. Graney will be responsible for the development and execution of the financial strategy and operations that support Vertex’s business plans, including the Finance, Accounting and Internal Audit functions. Mr. Graney most recently served as CFO and Senior Vice President of Finance and Corporate Strategy at Ironwood Pharmaceuticals.
“As Vertex continues its evolution to a leading global biotech, it is critical that we continue to build a strong and experienced leadership team,” said Ian Smith, Executive Vice President and Chief Operating Officer of Vertex. “Tom has the ideal blend of financial acumen, leadership skills, and industry experience that will be important as Vertex grows and expands as a global company.”
“I am thrilled to take on this important role with Vertex, a company that I have long admired for its unwavering commitment to patients and to discovering, developing and commercializing transformative medicines for people with serious and life-threatening diseases,” said Mr. Graney.
Tom Graney Biography
At Ironwood Pharmaceuticals, Mr. Graney was responsible for Finance, Corporate Strategy, Corporate Development, Quality, Supply Chain, IT, Corporate Communications and Investor Relations. Prior to joining Ironwood in 2014, he worked at Johnson & Johnson for approximately 20 years in both the U.S. and abroad, most recently serving as Worldwide VP of Finance and CFO for Ethicon Surgical Care.
Mr. Graney serves on the board of directors of AC Immune SA, a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases. He holds a B.S. in accounting from the University of Delaware and an M.B.A. in marketing, finance and international business from the Leonard N. Stern School of Business at New York University.
Source: Vertex
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
